Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Inclusion Criteria: Patients are eligible to be included in the study only if they met all the following criteria: * Female Patients must be ≥18 years old at diagnosis. * Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer and received olaparib from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required). * Patients must have a tumor BRCA testing result which is tBRCAwt, defined as tumor BRCA wild type (patients without evidence of BRCA 1 and/or BRCA 2 deleterious or suspected deleterious mutations). * Patients who have completed first-line platinum-based chemotherapy and were in clinical complete response (CR) or in partial response (PR). * Patients who were still in CR or PR before receiving maintenance therapy. * Patients who received at least one dose of olaparib tablets monotherapy as maintenance therapy within three months after platinum-based chemotherapy and without disease progression. Exclusion Criteria: Patients are excluded if any of the following factors were present: * Patient with multiple primary cancers as reported in EMR. * Concomitant any anti- cancer therapy (chemotherapy, immunotherapy, hormonal therapy (Hormone replacement therapy (HRT) is acceptable), radiotherapy, biological therapy or other novel agent) during Olaparib maintenance. * Any previous treatment with PARP inhibitor. * Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML. * Patients with symptomatic uncontrolled brain metastases. * Any other concerns related to decreased efficacy and safety of maintenance therapy.